How to Conduct Cross-Border Clinical Trials in Southeast Asia Under ASEAN Regulations

With the rapid growth of clinical research across emerging regions, Southeast Asia has become a hub for cross-border clinical trials. The ASEAN (Association of Southeast Asian Nations) bloc offers a unique opportunity for pharmaceutical companies to access diverse populations while leveraging evolving regulatory harmonization efforts. However, conducting clinical trials across multiple ASEAN countries involves navigating complex regulatory systems, ethics approvals, and operational logistics.

This guide provides an in-depth tutorial on how to efficiently manage cross-border trials in the ASEAN region—covering the ASEAN Common Technical Dossier (ACTD), national regulatory agencies, Good Clinical Practice (GCP) expectations, and submission best practices.

Why ASEAN Is Ideal for Cross-Border Trials:

Southeast Asia comprises ten nations—Brunei, Cambodia, Indonesia, Laos, Malaysia, Myanmar, the Philippines, Singapore, Thailand, and Vietnam. Together, they represent a population of over 650 million and offer:

• Disease burden diversity suitable for various therapeutic areas
• Cost-effective trial execution
• Improving healthcare infrastructure
• Strong patient recruitment potential
• Increasing regulatory maturity under ASEAN harmonization

However, regional variation in regulatory timelines, documentation requirements, and GCP enforcement means sponsors must carefully coordinate across countries.

ASEAN Harmonization: ACTD and ACTG Explained:

To support regulatory alignment, ASEAN developed two foundational tools:

• ASEAN Common Technical Dossier (ACTD): A harmonized structure for drug and clinical trial applications, modeled after ICH CTD
• ASEAN Clinical Trial Guidelines (ACTG): Regionally harmonized GCP principles and regulatory pathways for trial approval

These frameworks help streamline submissions across borders. Nevertheless, country-specific annexes, language requirements, and agency workflows remain distinct.

Key Regulatory Authorities in ASEAN:

To initiate trials in multiple ASEAN countries, sponsors must interact with the respective regulatory bodies:

• Malaysia – National Pharmaceutical Regulatory Agency (NPRA)
• Singapore – Health Sciences Authority (HSA)
• Thailand – Thai FDA
• Vietnam – Drug Administration of Vietnam (DAV)
• Philippines – FDA Philippines
• Indonesia – Badan POM

Each of these has specific application formats, review timelines, and interactions with their national ethics committees (ECs).

Submission Strategy for Multinational ASEAN Trials:

When conducting a trial across several ASEAN nations, sponsors should:

1. Use the ACTD format as a baseline for all submissions
2. Include local language translations where applicable (e.g., Vietnam, Indonesia)
3. Adapt Module 1 for country-specific administrative documents
4. Align trial protocols across all countries to avoid multiple amendments
5. Engage local CROs to manage regulatory intelligence and communications

Document consistency is vital for GCP compliance and regulatory clarity. SOPs must follow standardized processes such as those from Pharma SOP documentation.

Ethics Committee Coordination:

Each ASEAN country has separate EC procedures. A coordinated ethics submission strategy is essential:

• In some countries (e.g., Malaysia, Singapore), ethics and regulatory submissions can run in parallel
• Others require sequential review (regulatory first, then ethics)
• Submission requirements vary—some ECs request full trial protocols, others accept summaries

Maintaining version control across all submissions is critical to ensure consistency in investigator brochures, protocols, and informed consent documents.

Import Licenses and Investigational Product Approvals:

Most ASEAN nations require separate Import Licenses for investigational products (IP). The license process usually involves:

1. Application to national drug control authority
2. Labeling and packaging review
3. Stability data review (ideally aligned with Stability Studies principles)
4. Approval prior to IP shipment and site initiation

Customs documentation should match IP labels, batch numbers, and shipping records across trial countries to prevent delays.

Monitoring, Inspections, and Data Consistency:

Cross-border trials involve data collection across multiple countries, increasing risks of protocol deviation. GCP compliance must be actively maintained:

• Conduct joint monitoring visits when possible
• Train site personnel uniformly across all regions
• Ensure CRF (Case Report Form) data standards are identical
• Use centralized data management systems
• Prepare for unannounced inspections by authorities like TGA or SAHPRA

Trial master files and documentation should comply with GMP compliance protocols to withstand audits from all participating jurisdictions.

Challenges in ASEAN Cross-Border Trials:

Despite harmonization efforts, trial sponsors may face the following hurdles:

• Different definitions of “trial sponsor” and “legal representative”
• Varying data privacy and patient consent laws
• Complexity of aligning import-export processes
• Logistical challenges in shipping clinical supplies across borders
• Variable acceptance of foreign data or shared protocols

These require preemptive planning and adaptability in regulatory strategy.

Tips for Successful Execution:

1. Engage local consultants with knowledge of national laws
2. Develop a centralized project management framework with country-specific extensions
3. Track regulatory changes regularly in each country
4. Use bilingual documentation where needed
5. Apply quality standards equivalent to ICH-GCP and regional GCP requirements

Even with differing processes, common documentation standards like ACTD and electronic submission systems are helping unify the regulatory pathway.

Conclusion

Cross-border clinical trials in Southeast Asia present both immense opportunities and unique operational and regulatory challenges. By leveraging the ACTD format, coordinating ethics approvals, ensuring consistent data integrity, and maintaining open communication with ASEAN national authorities, sponsors can successfully navigate this complex yet promising environment.

The future of regional trial harmonization is optimistic, with continued collaboration and digital transformation expected to accelerate multinational research in the ASEAN bloc.

How to Manage Import and Export of Investigational Products in ASEAN Clinical Trials

The import and export of Investigational Products (IP) is a critical operational step in conducting clinical trials across the ASEAN region. Each member state has its own set of regulatory, customs, and documentation requirements that sponsors and clinical research organizations (CROs) must comply with. Navigating these differing standards is essential to avoid delays, ensure GMP compliance, and maintain the integrity of the product.

This article serves as a tutorial for regulatory affairs professionals, logistics coordinators, and sponsors looking to conduct clinical trials in Southeast Asia. We explore ASEAN-specific requirements for importing and exporting IPs, the necessary licenses and documents, and how to establish a harmonized logistics strategy across the region.

What Are Investigational Products?

Investigational Products are pharmaceutical forms of active ingredients or placebo being tested or used as a reference in a clinical trial. These include tablets, capsules, injectables, biologics, and vaccines. IPs must be handled with care, especially during cross-border transport, to ensure their identity, strength, quality, and purity remain intact.

Key Regulatory Stakeholders in ASEAN:

• Health Science Authority (HSA) – Singapore
• Drug Control Authority (DCA) – Malaysia
• Food and Drug Administration (FDA) – Philippines and Thailand
• Ministry of Health (MOH) – Vietnam, Indonesia, Cambodia, Laos
• National Ethics Committees and Customs Agencies

These authorities work in coordination with customs departments and ethics committees to regulate the entry and exit of clinical trial materials. Depending on the country, either the sponsor, CRO, or a local legal representative must initiate the import/export process.

Import License Requirements Across ASEAN:

1. Singapore:

The import of IPs requires a Clinical Trial Certificate (CTC) issued by HSA. Upon CTC approval, an import license is granted through the Pharmaceutical Regulatory Framework (PRISM) online portal. Cold chain products must meet GDP and temperature monitoring requirements.

2. Malaysia:

The DCA requires sponsors to apply for a Clinical Trial Import License (CTIL). A local licensed importer must handle customs clearance. For multi-site trials, each site must be listed in the CTIL application. Separate CTILs are needed for comparators or ancillary products.

3. Thailand:

Import permits are granted by the Thai FDA under the Ministry of Public Health. Sponsors must engage local importers registered with the FDA. Specific labeling, storage, and retention criteria apply, and the documentation must be in Thai.

4. Indonesia:

Importation of IPs must go through Badan POM (Indonesia’s National Agency of Drug and Food Control). The sponsor must partner with a locally registered entity and secure a Clinical Trial Notification (CTN) before initiating customs procedures.

5. Philippines:

Import licenses are granted by the Philippine FDA after ethics approval is secured from a PHREB-accredited committee. Importers must have a License to Operate (LTO). Customs clearance can be delayed if documents are incomplete or not in sync with the approved protocol.

6. Vietnam:

The Ministry of Health oversees IP importation through the Department of Science, Technology and Training (DSTT). A clinical trial approval letter must accompany the import license request. Temperature data loggers are often required for biologics or vaccines.

Other ASEAN countries follow similar procedures, although they may rely more heavily on manual submissions and paper-based documentation.

Essential Documents for IP Import/Export:

1. Clinical Trial Protocol and Investigator Brochure
2. Informed Consent Forms
3. Ethics Committee Approval Letter
4. Import License or CTIL/CTN Approval
5. Product Labeling Information and GMP Certificate
6. Customs Invoice and Packing List
7. Temperature Monitoring Plans and Storage Conditions
8. SOPs for IP Handling and Accountability

Using standardized Pharma SOP templates can streamline the preparation and review of these documents, reducing processing time.

Best Practices for ASEAN Import/Export Compliance:

• Engage with local regulatory consultants familiar with national nuances
• Ensure your logistics partner understands cold chain requirements
• Cross-check customs HS codes and labeling with local regulations
• Maintain an audit trail for each shipment, including deviations or delays
• Pre-clear shipments by sharing documentation in advance with customs brokers

For IPs with short shelf lives, real-time tracking and predictive logistics planning can mitigate risks associated with customs delays or port congestion.

ASEAN GCP and Import Oversight:

As part of the ASEAN GCP Guidelines, sponsors must ensure that the IP is manufactured and handled in accordance with Good Manufacturing Practices (GMP). Customs clearance is often contingent on the inclusion of a GMP certificate and cold chain SOPs.

According to CDSCO and USFDA expectations, compliance lapses in import/export documentation can lead to warning letters, delays, or trial termination. ASEAN countries are aligning increasingly with these expectations to maintain global credibility.

Common Challenges and Mitigation Strategies:

• Language Barriers: Translate critical documents into local languages as required
• Customs Delays: Pre-engage with national customs to understand evolving expectations
• Temperature Excursions: Use validated temperature monitoring devices with real-time alerts
• Labeling Non-compliance: Follow country-specific rules regarding expiry dates, language, and warnings

IP Export Considerations Post-Trial:

Once a trial concludes, IP destruction or re-export is governed by local rules. Sponsors must:

• Submit a close-out report to national regulatory authorities
• Request permission for destruction or re-export
• Provide reconciliation reports showing usage and inventory
• Maintain accountability logs for audit readiness

In some cases, ethics committees also require evidence that remaining IP was disposed of per protocol and without environmental harm.

Conclusion

The import and export of investigational products in ASEAN clinical trials requires meticulous planning, strong documentation, and clear understanding of country-specific requirements. Sponsors must collaborate with local partners, logistics experts, and customs brokers to streamline operations and avoid trial disruptions. Leveraging platforms like Stability Studies to track shelf life and cold chain integrity further strengthens compliance and quality assurance across multi-country studies.